Sample Page

Aclidinium bromide/formoterol, sold under the brand names Duaklir and Brimica, is a fixed-dose combination medication for inhalation, used in the management of chronic obstructive pulmonary disease (COPD).^[5] It consists of aclidinium bromide, a long-acting muscarinic antagonist, and formoterol, a long-acting β₂ agonist.^[3]^[4]

References

^ “Duaklir Genuair 340 micrograms /12 micrograms inhalation powder – Summary of Product Characteristics (SmPC)”. (emc). 9 September 2019. Archived from the original on 26 July 2020. Retrieved 26 July 2020.
^ “Duaklir Pressair- aclidinium bromide and formoterol fumarte powder, metered”. DailyMed. 3 July 2020. Retrieved 28 November 2020.
^ ^a ^b “Duaklir Genuair EPAR”. European Medicines Agency (EMA). 18 May 2018. Retrieved 26 July 2020.
^ ^a ^b “Brimica Genuair EPAR”. European Medicines Agency (EMA). 18 May 2018. Retrieved 26 July 2020.
^ D’Urzo AD, Singh D, Donohue JF, Chapman KR, Wise RA (September 2021). “Aclidinium bromide/formoterol fumarate as a treatment for COPD: an update”. Expert Review of Respiratory Medicine. 15 (9): 1093–1106. doi:10.1080/17476348.2021.1920403. PMID 34137664. S2CID 235460050.

“Aclidinium bromide”. Drug Information Portal. U.S. National Library of Medicine. Archived from the original on December 12, 2020.
“Formoterol fumarate”. Drug Information Portal. U.S. National Library of Medicine. Archived from the original on July 10, 2017.